WO2004071385A2 - Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention - Google Patents

Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention Download PDF

Info

Publication number
WO2004071385A2
WO2004071385A2 PCT/EP2004/001208 EP2004001208W WO2004071385A2 WO 2004071385 A2 WO2004071385 A2 WO 2004071385A2 EP 2004001208 W EP2004001208 W EP 2004001208W WO 2004071385 A2 WO2004071385 A2 WO 2004071385A2
Authority
WO
WIPO (PCT)
Prior art keywords
dipyridamole
stroke
angiotensin
antagonist
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/001208
Other languages
French (fr)
Other versions
WO2004071385A3 (en
Inventor
Lutz Hilbrich
James C. Gilbert
David Michael HUMPHREYS
Axel Riedel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32870338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004071385(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EA200501231A priority Critical patent/EA200501231A1/en
Priority to CA002515941A priority patent/CA2515941A1/en
Priority to SI200430789T priority patent/SI1603573T1/en
Priority to DK04709596T priority patent/DK1603573T3/en
Priority to MXPA05008572A priority patent/MXPA05008572A/en
Priority to JP2006501788A priority patent/JP2006517557A/en
Priority to BR0407457-2A priority patent/BRPI0407457A/en
Priority to DE602004013937T priority patent/DE602004013937D1/en
Priority to NZ542302A priority patent/NZ542302A/en
Priority to EP04709596A priority patent/EP1603573B8/en
Priority to YUP-2005/0618A priority patent/RS20050618A/en
Priority to HR20050713A priority patent/HRP20050713A2/en
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Priority to AU2004212305A priority patent/AU2004212305A1/en
Priority to US10/544,239 priority patent/US20070004687A1/en
Publication of WO2004071385A2 publication Critical patent/WO2004071385A2/en
Priority to UAA200508697A priority patent/UA83481C2/en
Publication of WO2004071385A3 publication Critical patent/WO2004071385A3/en
Anticipated expiration legal-status Critical
Priority to NO20054216A priority patent/NO20054216D0/en
Priority to US11/958,499 priority patent/US20080113949A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention relates to a method of preventing stroke or reducing the risk of stroke in a patient in need thereof, especially in a patient at risk for a stroke or a secondary stroke, using dipyridamole in combination with acetylsaiicyiic acid (ASA) and an angiotensin II antagonist, a pharmaceutical composition comprising a combination of dipyridamole, acetyl salicylic acid and an angiotensin II antagonist, and the use of dipyridamole for the manufacture of a corresponding pharmaceutical composition comprising a combination of dipyridamole, acetyl salicylic acid and an angiotensin II antagonist.
  • ASA acetylsaiicyiic acid
  • an angiotensin II antagonist an angiotensin II antagonist
  • Dipyridamole ⁇ 2,6-bis(diethanolamino)-4,8-dipiperidino-pyrimido[5,4-d]pyrimidine ⁇ , closely related substituted pyrimido-pyrimidines and their preparation have been described in e.g. U.S.Patent 3,031,450.
  • Dipyridamole was introduced as a coronary vasodilator in the early 1960s. It is also well known having platelet aggregation inhibitor properties due to the inhibition of adenosine uptake. Subsequently, dipyridamole was shown to reduce thrombus formation in a study of arterial circulation of the brain in a rabbit model.
  • Dipyridamole appears to inhibit thrombosis through multiple mechanisms. Early studies showed that it inhibits the uptake of adenosine, which was found to be a potent endogenous anti-thrombotic compound. Dipyridamole was also shown to inhibit cyclic AMP phosphodiesterase, thereby increasing intracellular c-AMP.
  • Dipyridamole also has antioxidant properties (Free Radic. Biol. Med. 1995; 18: 239- 247) that may contribute to its antithrombotic effect.
  • Low density lipoproteins become recognized by the scavenger receptor on macrophages, which is assumed to be the necessary step in the development of atherosclerosis (Ann. Rev. Med. 1992; 43: 219-25).
  • Angiotensin (ANG) II plays a major role in pathophysiology, especially as the most potent blood pressure increasing agent in humans. ANG II antagonists therefore are suitable for treating elevated blood pressure and congestive heart failure in a mammal. Examples of ANG II antagonists are described in EP-A-0 502 314, EP-A- 0 253 310 , EP-A-0 323 841 , EP-A-0 324 377, US-A-4,355,040 and US-A-4,880,804 .
  • Specific ANG II antagonists are sartans such as candesartan, eprosartan, irbesartan, losartan, telmisartan or valsartan, furthermore olmesartan and tasosartan.
  • ANG II besides its blood pressure increasing effect, additionally features growth promoting effects con.ributing to left ventricular hypertrophy, vascular thickening, atherosclerosis, renal failure and stroke.
  • Bradykinin exerts vasodilating and tissue protective actions, as disclosed for instance by W. Wienen et al.: Anti hypertensive and renoprotective effects of telmisartan after long term treatment in hypertensive diabetic (D) rats, 2nd. Int. Symposium on Angiotensin II Antagonism, February 15-18, 1999, The Queen Elizabeth II Conference Center, London, UK, Book of Abstracts, Abstract No. 50.
  • Losartan and irbesartan provide a renoprotective effect found within first clinical trials, as disclosed for instance by S. Andersen et al.: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy, Kidney Int 57 (2), 601-606 (2000).
  • ANG II antagonists selectively block the ATi receptor, leaving the AT 2 receptor, which plays a role in anti-growth and tissue regenerative actions, unopposed.
  • Completed clinical trials with Ang II antagonists appear to display similar blood pressure reducing and tissue protective effects as with ACE inhibitors, as disclosed forb instance by D.H.G. Smith et al.: Once-daily telmisartan compared with enalapril in the treatment of hypertension, Adv. Ther 1998, 15: 229-240, and by B.E. Karlberg et al.: Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension, J Hypertens 1999, 17: 293-302.
  • EP-A-1 013 273 discloses the use of ATi receptor antagonists or AT 2 receptor modulators for treating diseases associated with an increase of ATi receptors in subepithelial area or increase of AT 2 receptors in the epithelia, especially for treatment of several lung diseases.
  • dipyridamole when administered in combination with acetylsaiicyiic acid and an angiotensin II antagonist provides a stroke preventing effect superior to conventional medications or treatment regimes, for instance a combination regime of clopidogrel together with acetyl salicylic acid, especially in a patient at risk for a stroke or a secondary stroke.
  • ASA inhibits aggregation through direct effects on the platelet, in more detail, by irreversibly acetylating platelet cyclooxygenase, thus inhibiting the production of thromboxane, which is strongly thrombotic.
  • aspirin crosses over into endothelial cells N. Eng. J. Med.
  • the present invention provides a method of stroke prevention or reducing the risk of stroke or secondary stroke in a patient in need thereof, especially in a patient with elevated risk for stroke, e.g. in hypertensive patients or patients suffering from cerebrovascular disorders, said method comprising administering to said patient an effective amount of a pharmaceutical composition comprising dipyridamole or a pharmaceutically acceptable salt thereof in combination with ASA and an angiotensin II antagonist.
  • a pharmaceutical composition comprising dipyridamole or a pharmaceutically acceptable salt thereof in combination with ASA and an angiotensin II antagonist.
  • the main risk for a second stroke is a prior stroke due to degenerative processes in the wall of blood vessels supplying the brain. Patients at high risk of a second stroke with all its consequences readily seek preventive treatment.
  • the vascular pathobiology of ischaemic stroke is multiple and antithrombotic mechanisms in the cerebro-vascular microenvironment beyond platelet inhibition seem to be potentially disease-modifying and a means of reducing ischaemic stroke.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising dipyridamole or a pharmaceutically acceptable salt thereof in combination with ASA and an angiotensin II antagonist, adapted for simultaneous, separate or sequential administration.
  • the pharmaceutical composition according to the invention is meant to comprise a fixed dose combination comprising the active ingredients in one formulation together as well as
  • the present invention provides the use of dipyridamole or a pharmaceutically acceptable salt thereof in combination with ASA and an angiotensin II antagonist for the manufacture of a pharmaceutical composition for stroke prevention or reducing the risk of stroke or secondary stroke in a patient in need thereof.
  • the invention provides a new and improved approach for stroke prevention or reducing the risk of stroke or secondary stroke in a patient in need thereof, especially in a patient with elevated risk for stroke, comprising administering to the patient an effective amount of a pharmaceutical composition containing as acive ingredients dipyridamole or a pharmaceutically acceptable salt thereof in combination with ASA and an angiotensin II antagonist.
  • any of the oral dipyridamole retard, instant or the parenteral formulations on the market may be used, the retard formulations being preferred, for instance those available under the trademark Persantin ® , or, already in combination with ASA the formulations available under the trademark Asasantin ® or Aggrenox ® .
  • Suitable dipyridamole retard formulations are disclosed in EP-A-0032562, instant formulations are disclosed in EP-A-0068191 and combinations of ASA with dipyridamole are disclosed in EP-A-0257344 which are incorporated by reference.
  • Any Angiotensin II antagonist known in the art may be used in the method of prevention of the invention, e.g.
  • sartans such as candesartan, eprosartan, irbesartan, losartan, telmisartan (trademark Micardis ® ), valsartan, olmesartan or tasosartan, including the salts thereof or polymorphs thereof, using for instance the dosages disclosed in Rote Liste ® 2003, Editio Cantor Verlag Aulendorf, Germany, or in Physician's Desk Reference, 57 edition, 2003.
  • a plasma level of dipyridamole of about 0.2 to 5 ⁇ mol/L, preferably of about 0.5 to 2 ⁇ mol/L or particularly of about 0.8 to 1.5 ⁇ mol/L may be maintained.
  • Dipyridamole can be administered orally in a daily dosage of 50 to 750 mg, preferably 100 to 500 mg, most preferred 200 to 450 mg, for instance 200 mg twice a day.
  • this component of the ternary medication may be administered orally in a daily dosage of 10 to 200 mg, preferably 25 to 100 mg, most preferred 30 to 75 mg, for instance 25 mg twice a day.
  • the angiotensin II antagonist telmisartan is preferred.
  • This component can be administered orally in a daily dosage of 10 to 200 mg, for instance in a daily dosage of 20, 40, 80 or 160 mg, preferably in a daily dosage of 40 to 160 mg, most preferred 60 to 100 mg, for instance 20 or 40 mg once a day.
  • a specific method of prevention according to the invention comprises the combination of dipyridamole administered orally 200 mg twice a day, ASA administered orally 25 mg twice a day and telmisartan administered orally 20, 40 or 80 mg once a day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to a method of preventing stroke or reducing the risk of stroke in a patient in need thereof, especially in a patient at risk for a stroke or a secondary stroke, using dipyridamole in combination with acetylsalicylic acid (ASA) and an angiotensin II antagonist, corresponding pharmaceutical compositions, and the use of dipyridamole for the manufacture of a corresponding pharmaceutical composition comprising a combination of dipyridamole, acetyl salicylic acid and an angiotensin II antagonist.

Description

Use of dipyridamole in combination with acetylsaiicyiic acid and an angiotensin li antagonist for stroke prevention
Field of the Invention
This invention relates to a method of preventing stroke or reducing the risk of stroke in a patient in need thereof, especially in a patient at risk for a stroke or a secondary stroke, using dipyridamole in combination with acetylsaiicyiic acid (ASA) and an angiotensin II antagonist, a pharmaceutical composition comprising a combination of dipyridamole, acetyl salicylic acid and an angiotensin II antagonist, and the use of dipyridamole for the manufacture of a corresponding pharmaceutical composition comprising a combination of dipyridamole, acetyl salicylic acid and an angiotensin II antagonist.
Background of the Invention
Dipyridamole {2,6-bis(diethanolamino)-4,8-dipiperidino-pyrimido[5,4-d]pyrimidine}, closely related substituted pyrimido-pyrimidines and their preparation have been described in e.g. U.S.Patent 3,031,450. Dipyridamole was introduced as a coronary vasodilator in the early 1960s. It is also well known having platelet aggregation inhibitor properties due to the inhibition of adenosine uptake. Subsequently, dipyridamole was shown to reduce thrombus formation in a study of arterial circulation of the brain in a rabbit model. These investigations led to its use as an antithrombotic agent, it soon became the therapy of choice for such applications as stroke prevention, maintaining the patency of coronary bypass and valve- replacement, as well as for treatment prior to coronary angioplasty.
Furthermore, the European Stroke Prevention Study 2 (ESPS-2; J Neurol Sci. 1996; 143: 1-13; Neurology 1998; 51 : 17-19) proved that treatment by dipyridamole alone was as effective as low-dose aspirin in the reduction of stroke risk, and combination therapy with dipyridamole and aspirin was more than twice as effective as aspirin alone.
Dipyridamole appears to inhibit thrombosis through multiple mechanisms. Early studies showed that it inhibits the uptake of adenosine, which was found to be a potent endogenous anti-thrombotic compound. Dipyridamole was also shown to inhibit cyclic AMP phosphodiesterase, thereby increasing intracellular c-AMP.
Dipyridamole also has antioxidant properties (Free Radic. Biol. Med. 1995; 18: 239- 247) that may contribute to its antithrombotic effect. When oxidized, low density lipoproteins become recognized by the scavenger receptor on macrophages, which is assumed to be the necessary step in the development of atherosclerosis (Ann. Rev. Med. 1992; 43: 219-25).
The inhibition of free radical formation by dipyridamole has been found to inhibit fibrinogenesis in experimental liver fibrosis (Hepatology 1996; 24: 855-864) and to suppress oxygen radicals and proteinuria in experimental animals with amino- nucleoside nephropathy (Eur. J. Clin. Invest. 1998; 28: 877-883; Renal Physiol. 1984; 7: 218-226). Inhibition of lipid peroxidation also has been observed in human nonneoplastic lung tissue (Gen. Pharmacol. 1996; 27: 855-859).
Angiotensin (ANG) II plays a major role in pathophysiology, especially as the most potent blood pressure increasing agent in humans. ANG II antagonists therefore are suitable for treating elevated blood pressure and congestive heart failure in a mammal. Examples of ANG II antagonists are described in EP-A-0 502 314, EP-A- 0 253 310 , EP-A-0 323 841 , EP-A-0 324 377, US-A-4,355,040 and US-A-4,880,804 . Specific ANG II antagonists are sartans such as candesartan, eprosartan, irbesartan, losartan, telmisartan or valsartan, furthermore olmesartan and tasosartan.
It is known that ANG II, besides its blood pressure increasing effect, additionally features growth promoting effects con.ributing to left ventricular hypertrophy, vascular thickening, atherosclerosis, renal failure and stroke. Bradykinin, on the other hand, exerts vasodilating and tissue protective actions, as disclosed for instance by W. Wienen et al.: Anti hypertensive and renoprotective effects of telmisartan after long term treatment in hypertensive diabetic (D) rats, 2nd. Int. Symposium on Angiotensin II Antagonism, February 15-18, 1999, The Queen Elizabeth II Conference Center, London, UK, Book of Abstracts, Abstract No. 50.
Losartan and irbesartan provide a renoprotective effect found within first clinical trials, as disclosed for instance by S. Andersen et al.: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy, Kidney Int 57 (2), 601-606 (2000).
ANG II antagonists selectively block the ATi receptor, leaving the AT2 receptor, which plays a role in anti-growth and tissue regenerative actions, unopposed. Completed clinical trials with Ang II antagonists appear to display similar blood pressure reducing and tissue protective effects as with ACE inhibitors, as disclosed forb instance by D.H.G. Smith et al.: Once-daily telmisartan compared with enalapril in the treatment of hypertension, Adv. Ther 1998, 15: 229-240, and by B.E. Karlberg et al.: Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension, J Hypertens 1999, 17: 293-302.
EP-A-1 013 273 discloses the use of ATi receptor antagonists or AT2 receptor modulators for treating diseases associated with an increase of ATi receptors in subepithelial area or increase of AT2 receptors in the epithelia, especially for treatment of several lung diseases.
Summary of the Invention
It has now surprisingly been found that dipyridamole when administered in combination with acetylsaiicyiic acid and an angiotensin II antagonist provides a stroke preventing effect superior to conventional medications or treatment regimes, for instance a combination regime of clopidogrel together with acetyl salicylic acid, especially in a patient at risk for a stroke or a secondary stroke. ASA inhibits aggregation through direct effects on the platelet, in more detail, by irreversibly acetylating platelet cyclooxygenase, thus inhibiting the production of thromboxane, which is strongly thrombotic. In high doses, however, aspirin crosses over into endothelial cells (N. Eng. J. Med. 1984; 311 : 1206-1211), where it interrupts the production of prostacyclin, a potent natural inhibitor of platelet aggregation and by-product of the "arachidonic cascade" (N. Engl. J. Med. 1979; 300: 1142-1147). These observations led to the concept of low-dose antiplatelet therapy with ASA to maximize inhibition of thromboxane while minimizing the loss of prostacyclin (Lancet 1981; 1 : 969-971). In the method of prevention according to the invention a combination of low-dose ASA with dipyridamole and an angiotensin II antagonist is preferred.
Viewed from one aspect the present invention provides a method of stroke prevention or reducing the risk of stroke or secondary stroke in a patient in need thereof, especially in a patient with elevated risk for stroke, e.g. in hypertensive patients or patients suffering from cerebrovascular disorders, said method comprising administering to said patient an effective amount of a pharmaceutical composition comprising dipyridamole or a pharmaceutically acceptable salt thereof in combination with ASA and an angiotensin II antagonist. The main risk for a second stroke is a prior stroke due to degenerative processes in the wall of blood vessels supplying the brain. Patients at high risk of a second stroke with all its consequences readily seek preventive treatment. The vascular pathobiology of ischaemic stroke is multiple and antithrombotic mechanisms in the cerebro-vascular microenvironment beyond platelet inhibition seem to be potentially disease-modifying and a means of reducing ischaemic stroke.
Viewed from a second aspect the present invention provides a pharmaceutical composition comprising dipyridamole or a pharmaceutically acceptable salt thereof in combination with ASA and an angiotensin II antagonist, adapted for simultaneous, separate or sequential administration. The pharmaceutical composition according to the invention is meant to comprise a fixed dose combination comprising the active ingredients in one formulation together as well as
a kit of parts comprising
(a) a first containment containing a pharmaceutical composition comprising a therapeutically effective of dipyridamole; and
(b) a second containment containing a pharmaceutical composition comprising acetylsaiicyiic acid and a pharmaceutically acceptable carrier; and
(c) a third containment containing a pharmaceutical composition comprising an angiotensin II antagonist.
Viewed from a different aspect the present invention provides the use of dipyridamole or a pharmaceutically acceptable salt thereof in combination with ASA and an angiotensin II antagonist for the manufacture of a pharmaceutical composition for stroke prevention or reducing the risk of stroke or secondary stroke in a patient in need thereof.
Detailed Description of the Invention
The invention provides a new and improved approach for stroke prevention or reducing the risk of stroke or secondary stroke in a patient in need thereof, especially in a patient with elevated risk for stroke, comprising administering to the patient an effective amount of a pharmaceutical composition containing as acive ingredients dipyridamole or a pharmaceutically acceptable salt thereof in combination with ASA and an angiotensin II antagonist.
In the method of the invention any of the oral dipyridamole retard, instant or the parenteral formulations on the market may be used, the retard formulations being preferred, for instance those available under the trademark Persantin®, or, already in combination with ASA the formulations available under the trademark Asasantin® or Aggrenox®. Suitable dipyridamole retard formulations are disclosed in EP-A-0032562, instant formulations are disclosed in EP-A-0068191 and combinations of ASA with dipyridamole are disclosed in EP-A-0257344 which are incorporated by reference. Any Angiotensin II antagonist known in the art may be used in the method of prevention of the invention, e.g. the sartans such as candesartan, eprosartan, irbesartan, losartan, telmisartan (trademark Micardis®), valsartan, olmesartan or tasosartan, including the salts thereof or polymorphs thereof, using for instance the dosages disclosed in Rote Liste®2003, Editio Cantor Verlag Aulendorf, Germany, or in Physician's Desk Reference, 57 edition, 2003.
In the method of prevention according to the invention a plasma level of dipyridamole of about 0.2 to 5 μmol/L, preferably of about 0.5 to 2 μmol/L or particularly of about 0.8 to 1.5 μmol/L may be maintained. Dipyridamole can be administered orally in a daily dosage of 50 to 750 mg, preferably 100 to 500 mg, most preferred 200 to 450 mg, for instance 200 mg twice a day.
With respect to ASA this component of the ternary medication may be administered orally in a daily dosage of 10 to 200 mg, preferably 25 to 100 mg, most preferred 30 to 75 mg, for instance 25 mg twice a day.
With respect to the third component the angiotensin II antagonist telmisartan is preferred. This component can be administered orally in a daily dosage of 10 to 200 mg, for instance in a daily dosage of 20, 40, 80 or 160 mg, preferably in a daily dosage of 40 to 160 mg, most preferred 60 to 100 mg, for instance 20 or 40 mg once a day.
A specific method of prevention according to the invention comprises the combination of dipyridamole administered orally 200 mg twice a day, ASA administered orally 25 mg twice a day and telmisartan administered orally 20, 40 or 80 mg once a day.
With respect to all aspects of the invention the combination of dipyridamole, ASA and telmisartan is preferred, especially in the oral dosages indicated hereinbefore as most preferred.

Claims

1. A method of stroke prevention or reducing the risk of stroke or secondary stroke in a patient in need thereof, comprising administering to the patient an effective amount of a pharmaceutical composition comprising dipyridamole or a pharmaceutically acceptable salt thereof in combination with acetylsaiicyiic acid and an angiotensin II antagonist.
2. The method of claim 1 wherein the angiotensin II antagonist is telmisartan.
3. A pharmaceutical composition comprising dipyridamole or a pharmaceutically acceptable salt thereof, acetyl salicylic acid and an angiotensin II antagonist as a combined preparation for simultaneous, separate or sequential use.
4. The pharmaceutical composition of claim 3 wherein the angiotensin II antagonist is telmisartan.
5. The use of dipyridamole or a pharmaceutically acceptable salt thereof in combination with acetylsaiicyiic acid and an angiotensin II antagonist for the manufacture of a pharmaceutical composition for stroke prevention or reducing the risk of stroke or secondary stroke in a patient.
6. The use of claim 5 wherein the angiotensin II antagonist is telmisartan.
PCT/EP2004/001208 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention Ceased WO2004071385A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
US10/544,239 US20070004687A1 (en) 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ll antagonist for stroke prevention
YUP-2005/0618A RS20050618A (en) 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an ngiotensin ii antagonist for stroke prevention
SI200430789T SI1603573T1 (en) 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
DK04709596T DK1603573T3 (en) 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention
MXPA05008572A MXPA05008572A (en) 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention.
JP2006501788A JP2006517557A (en) 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and angiotensin II antagonists to prevent stroke attacks
BR0407457-2A BRPI0407457A (en) 2003-02-13 2004-02-10 Use of dipyridamole with acetylsalicylic acid and an angiotensin ii antagonist in the prevention of stroke
DE602004013937T DE602004013937D1 (en) 2003-02-13 2004-02-10 COMBINATION PREPARATIONS FOR THE PROTECTION OF FLAGS CONTAIN AN ATII ANTAGONIST
NZ542302A NZ542302A (en) 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention
EA200501231A EA200501231A1 (en) 2003-02-13 2004-02-10 APPLICATION OF DIPYRIDAMOL IN COMBINATION WITH ACETYLSALICYLIC ACID AND ANTAGONIST ANGIOTENZIN II FOR PREVENTION OF STROKE
HR20050713A HRP20050713A2 (en) 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
CA002515941A CA2515941A1 (en) 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
EP04709596A EP1603573B8 (en) 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
AU2004212305A AU2004212305A1 (en) 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention
UAA200508697A UA83481C2 (en) 2003-02-13 2004-10-02 Pharmaceutical composition of dipyridamole in combination with acetylsalicylic acid and angiotensin ii antagonist for preventing stroke
NO20054216A NO20054216D0 (en) 2003-02-13 2005-09-12 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention
US11/958,499 US20080113949A1 (en) 2003-02-13 2007-12-18 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10306179A DE10306179A1 (en) 2003-02-13 2003-02-13 Composition useful for preventing stroke comprises dipyridamole or its salt, acetyl salicylic acid and an angiotensin II antagonist
DE10306179.7 2003-02-13
EP03018212.5 2003-08-08
EP03018212 2003-08-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/958,499 Continuation US20080113949A1 (en) 2003-02-13 2007-12-18 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention

Publications (2)

Publication Number Publication Date
WO2004071385A2 true WO2004071385A2 (en) 2004-08-26
WO2004071385A3 WO2004071385A3 (en) 2005-01-06

Family

ID=32870338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/001208 Ceased WO2004071385A2 (en) 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention

Country Status (29)

Country Link
US (5) US20040214802A1 (en)
EP (2) EP1603573B8 (en)
JP (1) JP2006517557A (en)
KR (1) KR20050100676A (en)
CN (1) CN1750830A (en)
AR (1) AR043173A1 (en)
AT (1) ATE395921T1 (en)
AU (1) AU2004212305A1 (en)
BR (1) BRPI0407457A (en)
CA (1) CA2515941A1 (en)
DE (2) DE10306179A1 (en)
DK (1) DK1603573T3 (en)
EA (1) EA200501231A1 (en)
EC (1) ECSP055963A (en)
ES (1) ES2308147T3 (en)
HR (1) HRP20050713A2 (en)
MX (1) MXPA05008572A (en)
NO (1) NO20054216D0 (en)
NZ (1) NZ542302A (en)
PE (1) PE20050191A1 (en)
PL (1) PL378204A1 (en)
PT (1) PT1603573E (en)
RS (1) RS20050618A (en)
SI (1) SI1603573T1 (en)
TW (1) TW200501957A (en)
UA (1) UA83481C2 (en)
UY (1) UY28182A1 (en)
WO (1) WO2004071385A2 (en)
ZA (1) ZA200505956B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011680A1 (en) * 2003-07-31 2005-02-10 Boehringer Ingelheim International Gmbh Use of angiotensin ii receptor antagonists, especially telmisartan, in order to increase insulin sensitivity
WO2009080301A1 (en) * 2007-12-21 2009-07-02 Boehringer Ingelheim International Gmbh Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke
WO2010097501A3 (en) * 2009-02-26 2010-11-18 Orion Corporation A combination treatment of stroke
US12178817B2 (en) 2015-01-28 2024-12-31 Realinn Life Science Limited Compounds for enhancing PPARγ expression and nuclear translocation and therapeutic use thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10306179A1 (en) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Composition useful for preventing stroke comprises dipyridamole or its salt, acetyl salicylic acid and an angiotensin II antagonist
CA2437709A1 (en) * 2003-08-08 2005-02-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of dipyridamole, acetylsalicylic acid and an angiotensin ii antagonist for treatment and prevention of vascular events
JP2005060359A (en) * 2003-08-13 2005-03-10 Boehringer Ingelheim Pharma Gmbh & Co Kg Use of dipyridamole, acetylsalicylic acid and angiotensin II antagonists for the treatment and prevention of vascular pathologies
US20100069326A1 (en) * 2008-02-14 2010-03-18 Wasimul Haque Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders
WO2009100534A1 (en) * 2008-02-14 2009-08-20 Kardiatech, Inc. Combination therapy to treat vascular disorders
US8633158B1 (en) * 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031458A (en) * 1958-02-05 1962-04-24 Ciba Pharm Prod Inc Isoindolines
US3031450A (en) 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
US3317279A (en) * 1963-03-15 1967-05-02 Pennsalt Chemicals Corp Polymorph of calcium disilicide and its method of preparation
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
DE3000979A1 (en) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach NEW DIPYRIDAMOL RETARD FORMS AND METHOD FOR THEIR PRODUCTION
US4318477A (en) * 1980-09-22 1982-03-09 Kerpe Stase Z Pharmaceutical package
DE3124090A1 (en) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach NEW ORAL DIPYRIDAMOL FORMS
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DE3627423A1 (en) 1986-08-13 1988-02-18 Thomae Gmbh Dr K MEDICINAL PRODUCTS CONTAINING DIPYRIDAMOL OR MOPIDAMOL AND O-ACETYLSALICYL ACID OR THEIR PHYSIOLOGICALLY COMPATIBLE SALTS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR COMBATING THROMBUS FORMATION
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
SI9210098B (en) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoles, drugs with this compounds, and process for their preparation
EP1013273A1 (en) 1998-12-23 2000-06-28 Novartis AG Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
SE9903028D0 (en) * 1999-08-27 1999-08-27 Astra Ab New use
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
JP2002138054A (en) * 2000-08-25 2002-05-14 Takeda Chem Ind Ltd Fibrinogen lowering agent
JP2002293742A (en) * 2001-01-29 2002-10-09 Takeda Chem Ind Ltd Analgesic antiphlogistic
JP2003212758A (en) * 2001-03-16 2003-07-30 Takeda Chem Ind Ltd Method for producing sustained release preparation
DE10306179A1 (en) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Composition useful for preventing stroke comprises dipyridamole or its salt, acetyl salicylic acid and an angiotensin II antagonist

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011680A1 (en) * 2003-07-31 2005-02-10 Boehringer Ingelheim International Gmbh Use of angiotensin ii receptor antagonists, especially telmisartan, in order to increase insulin sensitivity
EA012600B1 (en) * 2003-07-31 2009-10-30 Бёрингер Ингельхайм Интернациональ Гмбх Use of angiotensin ii receptor antagonists and telmisartan in order to increase insulin sensitivity
EP2119441A1 (en) * 2003-07-31 2009-11-18 Boehringer Ingelheim International Gmbh Use of angiotensin II receptor antagonists in order to increase insulin sensitivity
AU2004260606B2 (en) * 2003-07-31 2010-12-09 Boehringer Ingelheim International Gmbh Use of angiotensin II receptor antagonists, especially telmisartan, in order to increase insulin sensitivity
EP2263670A1 (en) * 2003-07-31 2010-12-22 Boehringer Ingelheim Pharma GmbH & Co. KG Use of angiotensin II receptor antagonists in order to increase insulin sensitivity
EA017640B1 (en) * 2003-07-31 2013-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Pharmaceutical composition comprising telmisartan
WO2009080301A1 (en) * 2007-12-21 2009-07-02 Boehringer Ingelheim International Gmbh Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke
WO2010097501A3 (en) * 2009-02-26 2010-11-18 Orion Corporation A combination treatment of stroke
US12178817B2 (en) 2015-01-28 2024-12-31 Realinn Life Science Limited Compounds for enhancing PPARγ expression and nuclear translocation and therapeutic use thereof

Also Published As

Publication number Publication date
HRP20050713A2 (en) 2006-09-30
UA83481C2 (en) 2008-07-25
JP2006517557A (en) 2006-07-27
WO2004071385A3 (en) 2005-01-06
US20060241089A1 (en) 2006-10-26
AR043173A1 (en) 2005-07-20
BRPI0407457A (en) 2006-01-31
RS20050618A (en) 2007-09-21
ATE395921T1 (en) 2008-06-15
US20040214802A1 (en) 2004-10-28
DK1603573T3 (en) 2008-09-15
ECSP055963A (en) 2006-01-16
PE20050191A1 (en) 2005-04-12
PL378204A1 (en) 2006-03-20
MXPA05008572A (en) 2005-11-04
TW200501957A (en) 2005-01-16
DE10306179A1 (en) 2004-08-26
NZ542302A (en) 2008-12-24
US20070004687A1 (en) 2007-01-04
AU2004212305A1 (en) 2004-08-26
UY28182A1 (en) 2004-09-30
EP1603573A2 (en) 2005-12-14
EP1733729A1 (en) 2006-12-20
EP1603573B8 (en) 2009-04-01
US20080188497A1 (en) 2008-08-07
US20080113949A1 (en) 2008-05-15
NO20054216L (en) 2005-09-12
DE602004013937D1 (en) 2008-07-03
ES2308147T3 (en) 2008-12-01
NO20054216D0 (en) 2005-09-12
PT1603573E (en) 2008-06-26
CN1750830A (en) 2006-03-22
EA200501231A1 (en) 2006-02-24
CA2515941A1 (en) 2004-08-26
KR20050100676A (en) 2005-10-19
ZA200505956B (en) 2006-03-29
EP1603573B1 (en) 2008-05-21
SI1603573T1 (en) 2008-10-31

Similar Documents

Publication Publication Date Title
US20080113949A1 (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention
JP5757677B2 (en) Prevention and / or treatment of portal hypertension
CN100411620C (en) Use of dipyridamole or mopidamole for the preparation of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
KR20060007034A (en) Use of dipyridamole or furdamol to treat and prevent thromboembolic diseases and diseases and disorders caused by hyperplasia of thrombin and / or elevated expression of thrombin receptors
BRPI0620234A2 (en) pharmaceutical combination for treating luts comprising a pde5 inhibitor and a muscarinic antagonist
JP2002534477A (en) New use of melagatran
US20090075949A1 (en) Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
CA2566081A1 (en) Use of dipyridamole for treatment of resistance to platelet inhibitors
JP2006516593A (en) Use of dipyridamole or mopidamol for the treatment and prevention of MMP-9 dependent diseases
WO2010097501A2 (en) A combination treatment
US20080275011A1 (en) Use of dipyridamole, acetylsalicylic acid and an angiotensin ii antagonist for treatment and prevention of vascular events
KR20050018330A (en) Use of dipyridamole, acetylsalicylic acid and an angiotensin II antagonist for treatment and prevention of vascular events
JP2005060359A (en) Use of dipyridamole, acetylsalicylic acid and angiotensin II antagonists for the treatment and prevention of vascular pathologies
AU2003235004A1 (en) Use of dipyridamole, acetylsalicylic acid and an angiotensin II antagonist for treatment and prevention of vascular events
HK1089941A (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
MXPA03007462A (en) Use of dipyridamole, acetylsalicylic acid and an angiotensinii antagonist for treatment and prevention of vascular events.
WO2009080301A1 (en) Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke
Van Dyke et al. Drugs Used in Gout
TW200522965A (en) Novel pharmaceutical combination comprising pyrimido-pyrimidine in combination with one other active component for treatment and prevention of fibrin-dependent microcirculation disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200501153

Country of ref document: VN

Ref document number: P-2005/0618

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1-2005-501441

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2004709596

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005/05956

Country of ref document: ZA

Ref document number: 200505956

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 3517/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 378204

Country of ref document: PL

Ref document number: 2515941

Country of ref document: CA

Ref document number: 170234

Country of ref document: IL

Ref document number: 1020057014826

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: P20050713A

Country of ref document: HR

Ref document number: PA/a/2005/008572

Country of ref document: MX

Ref document number: 2006501788

Country of ref document: JP

Ref document number: 20048041078

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 200501231

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 542302

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004212305

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 05092660

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2004212305

Country of ref document: AU

Date of ref document: 20040210

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004212305

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020057014826

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004709596

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 492/DELNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: PI0407457

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2007004687

Country of ref document: US

Ref document number: 10544239

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10544239

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2004709596

Country of ref document: EP